{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:16:27Z","timestamp":1793834187351,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Applied Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Diabetic cardiomyopathy (DbCM) is a form of Stage B heart failure (HF) at high risk for progression to overt disease. Using baseline characteristics of study participants from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF) Trial we sought to characterize clinical characteristics of individuals with findings consistent with DbCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Among study participants meeting inclusion criteria, clinical characteristics, laboratory testing, imaging, Kansas City Cardiomyopathy Questionnaire (KCCQ), Physical Activity Scale of the Elderly (PASE) and cardiopulmonary exercise testing (CPET) results were tabulated. Cluster phenogroups were identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 691 study participants (mean age 67.4 years; 50% were female), mean duration of type 2 diabetes mellitus (T2DM) was 14.5 years. The median (Q1, Q3) N-terminal pro-B type natriuretic peptide and high sensitivity cardiac troponin T were 71 (35, 135) ng\/L and 9 [6, 12] ng\/L. The most common echocardiographic abnormalities were reduced global longitudinal strain in 25.3% and impaired diastolic relaxation in 17.7%. Despite rather well-preserved KCCQ scores the average PASE score was markedly impaired at 155 accompanied by an average maximal oxygen consumption of 15.7 mL\/Kg\/minute on CPET. In K-means clustering, 4 phenogroups were identified including a higher-risk group with more advanced age, greater elevation of cardiac biomarkers, and more prevalent evidence for diastolic dysfunction and left ventricular hypertrophy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Baseline data from the ARISE-HF Trial provide clinical characterization of individuals with T2DM and features of stage B HF, and may help clarify the diagnosis of DbCM.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>ARISE-HF, NCT04083339.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02135-z","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:02:33Z","timestamp":1706799753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial"],"prefix":"10.1186","volume":"23","author":[{"given":"James L.","family":"Januzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrien E.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H.","family":"Wilson Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mohebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Urbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Perfetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"issue":"6","key":"2135_CR1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595\u2013602.","journal-title":"Am J Cardiol"},{"issue":"9","key":"2135_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585\u2013607.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2135_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.pcad.2019.03.003","volume":"62","author":"G Murtaza","year":"2019","unstructured":"Murtaza G, Virk HUH, Khalid M, Lavie CJ, Ventura H, Mukherjee D, et al. Diabetic cardiomyopathy - A comprehensive updated review. Prog Cardiovasc Dis. 2019;62(4):315\u201326.","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"2135_CR4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"key":"2135_CR5","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al. Universal Definition and classification of Heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart failure. J Card Fail. 2021.","DOI":"10.1002\/ejhf.2115"},{"issue":"4","key":"2135_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1479164115579006","volume":"12","author":"CS Lam","year":"2015","unstructured":"Lam CS. Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res. 2015;12(4):234\u20138.","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"2135_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.106.634949","volume":"115","author":"AI Vinik","year":"2007","unstructured":"Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387\u201397.","journal-title":"Circulation"},{"issue":"1","key":"2135_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13098-023-00998-y","volume":"15","author":"J Deng","year":"2023","unstructured":"Deng J, Yan F, Tian J, Qiao A, Yan D. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy. Diabetol Metab Syndr. 2023;15(1):35.","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"2135_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2018.02.010","volume":"39","author":"X Palomer","year":"2018","unstructured":"Palomer X, Pizarro-Delgado J, Vazquez-Carrera M. Emerging actors in Diabetic Cardiomyopathy: heartbreaker biomarkers or therapeutic targets? Trends Pharmacol Sci. 2018;39(5):452\u201367.","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"2135_CR10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jcmg.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B Heart failure in type 2 diabetes Mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11(10):1390\u2013400.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2135_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fendo.2018.00729","volume":"9","author":"J Zheng","year":"2018","unstructured":"Zheng J, Cheng J, Zheng S, Zhang L, Guo X, Zhang J, et al. Physical Exercise and its Protective effects on Diabetic Cardiomyopathy: what is the evidence? Front Endocrinol (Lausanne). 2018;9:729.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2135_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-020-01109-1","volume":"19","author":"L Nesti","year":"2020","unstructured":"Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2135_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12933-022-01618-1","volume":"21","author":"L Nesti","year":"2022","unstructured":"Nesti L, Pugliese NR, Sciuto P, Trico D, Dardano A, Baldi S, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial. Cardiovasc Diabetol. 2022;21(1):181.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"2135_CR14","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/eurjpc\/zwaa129","volume":"28","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, De Biase N, Gargani L, Mazzola M, Conte L, Fabiani I, et al. Predicting the transition to and progression of heart failure with preserved ejection fraction: a weighted risk score using bio-humoural, cardiopulmonary, and echocardiographic stress testing. Eur J Prev Cardiol. 2021;28(15):1650\u201361.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"2135_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10741-021-10194-7","volume":"28","author":"NR Pugliese","year":"2023","unstructured":"Pugliese NR, Pieroni A, De Biase N, Di Fiore V, Nesti L, Agostoni P, et al. Impact of diabetes on cardiopulmonary function: the added value of a combined cardiopulmonary and echocardiography stress test. Heart Fail Rev. 2023;28(3):645\u201355.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"2135_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, Ritchie R, Shaw JE, Kaye D. Implications of underlying mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2135_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1210\/er.2003-0012","volume":"25","author":"ZY Fang","year":"2004","unstructured":"Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543\u201367.","journal-title":"Endocr Rev"},{"issue":"11","key":"2135_CR18","first-page":"1241","volume":"15","author":"E Aksakal","year":"2011","unstructured":"Aksakal E, Akaras N, Kurt M, Tanboga IH, Halici Z, Odabasoglu F, et al. The role of oxidative stress in diabetic cardiomyopathy: an experimental study. Eur Rev Med Pharmacol Sci. 2011;15(11):1241\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2135_CR19","doi-asserted-by":"crossref","unstructured":"De Geest B, Mishra M. Role of oxidative stress in Diabetic Cardiomyopathy. Antioxid (Basel). 2022;11(4).","DOI":"10.3390\/antiox11040784"},{"key":"2135_CR20","doi-asserted-by":"crossref","unstructured":"Dhalla NS, Shah AK, Tappia PS. Role of oxidative stress in metabolic and subcellular abnormalities in Diabetic Cardiomyopathy. Int J Mol Sci. 2020;21(7).","DOI":"10.3390\/ijms21072413"},{"issue":"6","key":"2135_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jdi.12250","volume":"5","author":"Q Liu","year":"2014","unstructured":"Liu Q, Wang S, Cai L. Diabetic cardiomyopathy and its mechanisms: role of oxidative stress and damage. J Diabetes Investig. 2014;5(6):623\u201334.","journal-title":"J Diabetes Investig"},{"issue":"4","key":"2135_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/157340310793566145","volume":"6","author":"K Watanabe","year":"2010","unstructured":"Watanabe K, Thandavarayan RA, Harima M, Sari FR, Gurusamy N, Veeraveedu PT, et al. Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy. Curr Cardiol Rev. 2010;6(4):280\u201390.","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"2135_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-023-01811-w","volume":"22","author":"K Gopal","year":"2023","unstructured":"Gopal K, Karwi QG, Tabatabaei Dakhili SA, Wagg CS, Zhang L, Sun Q, et al. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023;22(1):73.","journal-title":"Cardiovasc Diabetol"},{"key":"2135_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ahj.2022.11.003","volume":"256","author":"JL Januzzi Jr","year":"2023","unstructured":"Januzzi JL Jr., Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CSP, et al. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart failure trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. Am Heart J. 2023;256:25\u201336.","journal-title":"Am Heart J"},{"issue":"2","key":"2135_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0895-4356(93)90053-4","volume":"46","author":"RA Washburn","year":"1993","unstructured":"Washburn RA, Smith KW, Jette AM, Janney CA. The physical activity scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153\u201362.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"2135_CR26","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, et al. Heart failure: an underappreciated complication of diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670\u201390.","journal-title":"Diabetes Care"},{"issue":"1","key":"2135_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-021-01314-6","volume":"20","author":"L Nesti","year":"2021","unstructured":"Nesti L, Pugliese NR, Sciuto P, De Biase N, Mazzola M, Fabiani I, et al. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):124.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2135_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","volume":"12","author":"G Jia","year":"2016","unstructured":"Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2135_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21\u20138.","journal-title":"Diabetologia"},{"issue":"1","key":"2135_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/dom.14861","volume":"25","author":"L Nesti","year":"2023","unstructured":"Nesti L, Pugliese NR, Chiriaco M, Trico D, Baldi S, Natali A. Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function. Diabetes Obes Metab. 2023;25(1):177\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2135_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-020-01044-1","volume":"19","author":"Y Gao","year":"2020","unstructured":"Gao Y, Ren Y, Guo YK, Liu X, Xie LJ, Jiang L, et al. Metabolic syndrome and myocardium steatosis in subclinical type 2 diabetes mellitus: a (1)H-magnetic resonance spectroscopy study. Cardiovasc Diabetol. 2020;19(1):70.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2135_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12933-019-0940-z","volume":"18","author":"EHM Paiman","year":"2019","unstructured":"Paiman EHM, van Eyk HJ, Bizino MB, Dekkers IA, de Heer P, Smit JWA, et al. Phenotyping diabetic cardiomyopathy in europeans and South asians. Cardiovasc Diabetol. 2019;18(1):133.","journal-title":"Cardiovasc Diabetol"},{"issue":"16","key":"2135_CR33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2021.08.020","volume":"78","author":"MW Segar","year":"2021","unstructured":"Segar MW, Khan MS, Patel KV, Butler J, Tang WHW, Vaduganathan M, et al. Prevalence and prognostic implications of Diabetes with Cardiomyopathy in Community-Dwelling adults. J Am Coll Cardiol. 2021;78(16):1587\u201398.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02135-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02135-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:06:20Z","timestamp":1706799980000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02135-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02135-z","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"2 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were approved by Institutional Review Boards, and all study participants provided consent for inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent"}},{"value":"Dr. Januzzi is a Trustee of the American College of Cardiology, is a Board member of Imbria Pharmaceuticals, has received research support from Abbott, Applied Therapeutics, HeartFlow Inc, Innolife and Roche Diagnostics, consulting income from Abbott, AstraZeneca, Bayer, Beckman, Boehringer-Ingelheim, Janssen, Novartis, Merck, and Roche Diagnostics, and participates in clinical endpoint committees\/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer and Takeda; Dr. Del Prato has served as president of EASD\/European Foundation for the Study of Diabetes (EFSD) (2020\u20132022); has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has served as advisor for Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., Novo Nordisk, Sanofi and Sun Pharmaceuticals; and has received fees for speaking from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Merck Sharpe & Dohme and Novo Nordisk. Dr. Rosenstock has served on scientific advisory boards and received honorarium or consulting fees from Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eli Lilly, Endogenex, Hanmi, Novo Nordisk, Oramed, Regor, Sanofi, Scholar Rock, Structure Therapeutics, Terns Pharma and Zealand; and has received grants\/research support from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi, Merck, Oramed, Novartis, Novo Nordisk, Pfizer and Sanofi. Dr. Butler is a consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation, and Vifor; Dr. Ezekowitz reports research support for trial leadership or grants from American Regent, Applied Therapeutics, AstraZeneca, Bayer, Cytokinetics, Merck & Co, Novo Nordisk, Otsuka; honoraria for consultancy from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Otsuka; serves as an advisor to US2.ai\u2026.Dr. Ibrahim reports consulting income from Cytokinetics and honoraria from Applied Therapeutics; Dr. Tang is a consultant for Sequana Medical, Cardiol Therapeutics Inc, Genomics plc, Zehna Therapeutics, Renovacor, Boston Scientific, WhiteSwell, Kiniksa Pharmaceuticals, Intellia Therapeutics, CardiaTec Biosciences and has received honorarium from Springer, Belvoir Media Group, and American Board of Internal Medicine; Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has Received research support from NovoNordisk and Roche Diagnostics; has Served as consultant or on the Advisory Board\/ Steering Committee\/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape\/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai. Dr. Zannad reports personal fees from 89bio, Applied Therapeutics, Bayer, Betagenon, Biopeutics, Boehringer, BMS, CVRx, Cardior, Cambrian, Cereno pharmaceutical, Cellprothera, CEVA, Merck, Northsea, Novartis, NovoNordisk, Otsuka, Owkin, Salubris, Servier, having stock options at G3Pharmaceutical and equities at Cereno pharmaceutical, Cardiorenal, Eshmoun Clinical research and being the founder of CVCT. Drs. Urbinati and Perfetti are employees of Applied Therapeutics, Inc. the rest of the authors have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}